Table 2.

PK bioequivalence ratios of PK parameters for salicylic acid concentrations of PL-ASA and (plain) IR-ASA at 325 and 650 mg doses

	Ratio (%)a	90% CIb	p valuec
Salicylic acid parameters, 325 mg dose (n = 13)
Cmax, ng/mL	104	92–117	0.59
AUC0-t, ng×min/mL	97	89–104	0.43
AUC0-∞, ng×min/mL	98	91–106	0.62
Salicylic acid parameters, 650 mg dose (n = 14)
Cmax, ng/mL	106	97–115	0.25
AUC0-t, ng×min/mL	98	93–103	0.44
AUC0-∞, ng×min/mL	99	95–103	0.65

Source: Angiolillo et al. [48]

AUC area under the concentration-time curve, AUC_0-t AUC from time 0 to the time t of the last measurable concentration, AUC_0-∞ AUC from time zero to infinity, C_max peak plasma concentration, CI confidence interval, IR-ASA immediate-release aspirin, PK pharmacokinetic, PL-ASA phospholipid-aspirin complex

^aRatio = 100 × geometric mean (PL-ASA)/geometric mean (IR-ASA)

^b90% confidence interval on the ratio of PL-ASA to IR-ASA

^cANOVA p-value for the difference in the treatment estimates